Log In
Beyfortus (Nirsevimab) Immunization and Reimbursement
Beyfortus (nirsevimab), a monoclonal antibody, is administered to newborns and infants once during their first RSV season and again in the second RSV season to children up to 19 months of age, as clinically indicated by Advisory Committee on Immunization Practices’ (ACIP) and American Academy of Pediatrics (AAP). AMA’s CPT Editorial Panel approved CPT codes 90380-90381 in May 2023 and released June 2023. The administration code with nirsevimab is 96372 (injection, subcutaneous or intramuscular).
Blue Cross and Blue Shield of North Carolina (Blue Cross NC) has reviewed the information on nirsevimab and will reimburse providers for the immunization. If an evaluative or preventative service is being coded and billed with administration of nirsevimab, it must be appended with an appropriate modifier, such as -25 or -59, to indicate the services are separate and distinct.
Blue Cross and Blue Shield of North Carolina does not discriminate on the basis of race, color, national origin, sex, age or disability in its health programs and activities. Learn more about our non-discrimination policy and no-cost services available to you.
Information in other languages: Español 中文 Tiếng Việt 한국어 Français العَرَبِيَّة Hmoob ру́сский Tagalog ગુજરાતી ភាសាខ្មែរ Deutsch हिन्दी ລາວ 日本語
© 2024 Blue Cross and Blue Shield of North Carolina. ®, SM Marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield plans. All other marks and names are property of their respective owners. Blue Cross and Blue Shield of North Carolina is an independent licensee of the Blue Cross and Blue Shield Association.